Disopyramidum [Inn-Latin]
Brand names,
Disopyramidum [Inn-Latin]
Analogs
Disopyramidum [Inn-Latin]
Brand Names Mixture
Disopyramidum [Inn-Latin]
Chemical_Formula
C21H29N3O
Disopyramidum [Inn-Latin]
RX_link
http://www.rxlist.com/cgi/generic2/disopyr.htm
Disopyramidum [Inn-Latin]
fda sheet
Disopyramidum [Inn-Latin]
msds (material safety sheet)
Disopyramidum [Inn-Latin]
Synthesis Reference
No information avaliable
Disopyramidum [Inn-Latin]
Molecular Weight
339.475 g/mol
Disopyramidum [Inn-Latin]
Melting Point
94.5-95 oC
Disopyramidum [Inn-Latin]
H2O Solubility
44.9 mg/L
Disopyramidum [Inn-Latin]
State
Solid
Disopyramidum [Inn-Latin]
LogP
3.972
Disopyramidum [Inn-Latin]
Dosage Forms
Capsule; Tablet (extended-release)
Disopyramidum [Inn-Latin]
Indication
For the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, ventricular pre-excitation and cardiac dysrhythmias.
Disopyramidum [Inn-Latin]
Pharmacology
Disopyramide is an antiarrhythmic drug indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia that are life-threatening. In man, Disopyramide at therapeutic plasma levels shortens the sinus node recovery time, lengthens the effective refractory period of the atrium, and has a minimal effect on the effective refractory period of the AV node. Little effect has been shown on AV-nodal and His-Purkinje conduction times or QRS duration. However, prolongation of conduction in accessory pathways occurs.
Disopyramidum [Inn-Latin]
Absorption
Nearly complete
Disopyramidum [Inn-Latin]
side effects and Toxicity
LD50=580 mg/kg in rats
Disopyramidum [Inn-Latin]
Patient Information
No information avaliable
Disopyramidum [Inn-Latin]
Organisms Affected
Humans and other mammals